May 24, 2024 11:24 AM EDTUpdated 01:50 PM
R&D

#AS­CO24: A roundup of the lat­est da­ta from Merus, Mor­phoSys and oth­ers

ENDPOINTS

Read on for news about Im­muno­core, Ar­cus, CG On­col­o­gy, Gen­mab, Mer­ck and GSK:

Merus stock spikes on da­ta in head and neck squa­mous cell car­ci­no­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times